GENI
NEUTRALGENinCode Plc Announces Change in Shareholding
The healthcare diagnostics company has announced a change in shareholding, with Dowgate Group Limited reducing its stake in the business.
GENinCode
3.6000GBX
0.00%
Market Cap
10.33M
Volume
365.7k
33% of avg
P/E Ratio
-1.80
EPS (TTM)
-2
Beta
0.87
Day Range
3.2000p - 4.0000p
52 Week Range
1.0000p3.6000p8.5000p
3.6000p
Upcoming Events
Early Q1 2026
Expected submission of additional information for CARDIO inCode-Score FDA De Novo classification
High Impact Event
GENI
BADGENinCode Reports Revenue Growth but Lowers Full-Year Expectations Amid NHS Challenges and FDA Delays
The genetic testing firm reported revenue growth but faces headwinds from NHS restructuring and FDA approval delays, leading to lowered full-year expectations despite some positive developments in key markets.
GENI
NEUTRALGENinCode Plc Launches ROCA Test Surveillance Service for High-Risk Women
The healthcare company has launched a new surveillance service for women at high risk of ovarian cancer, working with NHS partners.
GENI
NEUTRALGENinCode Plc Announces Holding(s) in Company
The healthcare diagnostics company has announced changes to its major shareholders, with Maven Capital Partners UK LLP increasing its stake.
GENI
NEUTRALGENinCode Provides Update on Share Price Movement
The healthcare company provides a statement regarding recent share price movements, noting no specific reason for the changes.
GENI
NEUTRALGENinCode Plc Announces Notice of Results
The healthcare company announces the upcoming release of its interim results and plans for analyst and investor briefings.
GENI
NEUTRALGENinCode Reports 15% Revenue Growth in H1 2025
The healthcare diagnostics company reports a 15% increase in revenues for the first half of 2025, but also mentions ongoing regulatory and commercial discussions that suggest potential short-term challenges.
GENI
NEUTRALGENinCode Provides Update on FDA De Novo Submission
The genetics company focused on cardiovascular disease prevention provides an update on its FDA De Novo submission, indicating progress but remaining uncertainty.
GENI
NEUTRALGENinCode Reports 25% Revenue Growth Amid Ongoing Losses
The genetic testing firm reported a 25% revenue increase but continues to operate at a loss. Despite market expansions and regulatory progress, financial challenges persist amid a competitive landscape and economic uncertainties.
GENI
NEUTRALGENinCode Plc Announces Notice of Results
The healthcare company announces the release of its audited final results and upcoming analyst and investor briefings.